Zacks: Brokerages Expect Dermira Inc (DERM) Will Announce Quarterly Sales of $34.16 Million

Share on StockTwits

Equities analysts predict that Dermira Inc (NASDAQ:DERM) will report $34.16 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Dermira’s earnings, with the highest sales estimate coming in at $34.60 million and the lowest estimate coming in at $33.37 million. Dermira posted sales of $39.08 million during the same quarter last year, which suggests a negative year over year growth rate of 12.6%. The business is expected to report its next quarterly earnings results on Monday, August 5th.

According to Zacks, analysts expect that Dermira will report full-year sales of $67.97 million for the current fiscal year, with estimates ranging from $49.60 million to $103.72 million. For the next year, analysts expect that the firm will post sales of $64.97 million, with estimates ranging from $43.70 million to $101.10 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Dermira.

Dermira (NASDAQ:DERM) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.39). The company had revenue of $2.45 million during the quarter, compared to analysts’ expectations of $2.63 million. Dermira had a negative return on equity of 391.86% and a negative net margin of 510.47%.

A number of equities analysts have weighed in on the company. Zacks Investment Research cut Dermira from a “hold” rating to a “sell” rating in a report on Wednesday, April 3rd. Mizuho upped their price target on Dermira from $10.00 to $17.00 and gave the stock a “positive” rating in a report on Thursday, March 21st. They noted that the move was a valuation call. Cantor Fitzgerald restated a “buy” rating and issued a $20.00 price target on shares of Dermira in a report on Tuesday, April 2nd. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target (up previously from $16.00) on shares of Dermira in a report on Monday, March 25th. Finally, HC Wainwright upped their price target on Dermira from $13.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, March 27th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $18.30.

In other news, insider Eugene A. Bauer sold 35,000 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $15.00, for a total transaction of $525,000.00. Following the completion of the transaction, the insider now directly owns 43,900 shares in the company, valued at approximately $658,500. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 14.80% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Fifth Third Bancorp purchased a new position in shares of Dermira during the 1st quarter valued at approximately $44,000. Advisor Group Inc. boosted its stake in shares of Dermira by 117.0% during the 1st quarter. Advisor Group Inc. now owns 6,062 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 3,269 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of Dermira by 32.0% during the 1st quarter. HighTower Advisors LLC now owns 17,244 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 4,181 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Dermira by 1.6% during the 1st quarter. Northern Trust Corp now owns 439,374 shares of the biopharmaceutical company’s stock valued at $5,954,000 after buying an additional 7,103 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of Dermira by 48,273.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,256 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 7,241 shares during the last quarter. Institutional investors own 83.38% of the company’s stock.

NASDAQ DERM traded down $0.23 on Thursday, reaching $9.72. The company had a trading volume of 688,289 shares, compared to its average volume of 1,620,368. The stock has a market cap of $522.21 million, a PE ratio of -1.85 and a beta of 1.32. Dermira has a 1 year low of $6.00 and a 1 year high of $15.48. The company has a quick ratio of 6.92, a current ratio of 7.13 and a debt-to-equity ratio of 4.36.

Dermira Company Profile

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Read More: What is a resistance level?

Get a free copy of the Zacks research report on Dermira (DERM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Limestone Bancorp  vs. Centerstate Bank  Head to Head Analysis
Limestone Bancorp vs. Centerstate Bank Head to Head Analysis
Beasley Broadcast Group  & Spotify Technology  Head to Head Contrast
Beasley Broadcast Group & Spotify Technology Head to Head Contrast
Contrasting MacroGenics  & Prana Biotechnology
Contrasting MacroGenics & Prana Biotechnology
Contrasting Nexstar Media Group  & FOX
Contrasting Nexstar Media Group & FOX
Contrasting Superior Industries International  and Adomani
Contrasting Superior Industries International and Adomani
Renasant  & Sierra Bancorp  Head-To-Head Review
Renasant & Sierra Bancorp Head-To-Head Review


© 2006-2019 Ticker Report